Peptides
NAD+ is a coenzyme, not a peptide. A small human infusion study tracked NAD+ metabolites, not energy, aging, or performance outcomes. It cannot establish a therapeutic benefit or standard infusion dose.
Peptides
L-carnitine transports fatty acids into mitochondria and has medical uses in deficiency. Human supplement studies show mixed exercise and weight-loss results; oral study doses do not validate a catalog injection vial.
Peptides
5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide. Mouse studies found changes in adiposity and metabolic markers; human weight-loss efficacy, long-term safety, and dosing remain unestablished.
Peptides
Thymogen is a synthetic Glu-Trp dipeptide. An older placebo-controlled surgical study reported immune-marker and postoperative findings, but it does not establish routine immune support or an injection regimen for healthy adults.
Peptides
Testagen (KEDG) is marketed for testicular and hormone support, but published evidence for the exact peptide is primarily laboratory work. Human testosterone, fertility, and safety benefits have not been established.
Peptides
Prostamax produced a response in rat prostate-tissue culture. No controlled clinical evidence shows it improves urinary symptoms or treats prostate disease.
Peptides
Pinealon showed neuroprotective signals in a prenatal rat model. That does not establish better memory, brain repair, or a dose for adults.
Peptides
Ovagen is marketed as the EDL short peptide for kidney and liver support. The strongest directly relevant evidence is in rat kidney-injury models, not patients.
Peptides
Cortagen (AEDP) has changed gene expression in mouse tissue and been studied in animal nerve models. Those results do not establish human brain or nerve benefits.
Peptides
The AED peptide changed cartilage-related markers in cultured human stem cells. That is an early laboratory signal, not proof of restored cartilage or less joint pain in patients.
Peptides
Cardiogen has shown effects in rat heart-tissue cultures. There is no demonstrated benefit for human heart function or disease from the catalog vial.
Peptides
Bronchogen has been studied in rat lung tissue grown outside the body. That does not establish improved breathing, lung healing, or a human dose.
Peptides
The Wolverine vial pairs BPC-157 with supplier-labeled TB500/TB4. A tiny uncontrolled knee-pain chart review is not evidence that this premixed blend heals injuries.
Peptides
VIP has physiological effects in lungs, blood vessels, and immune signaling. A large hospitalized COVID-19 trial of intravenous aviptadil did not improve clinical outcomes.
Peptides
Thymulin changed inflammatory measures in a mouse autoimmune-disease model, but that does not establish a general immune or anti-inflammatory treatment in people.
Peptides
Tesamorelin and ipamorelin act on different growth-hormone pathways, but a vial combining them has not been shown to reduce visceral fat or improve recovery in a controlled human trial.
Peptides
The 889 Da TB-500 fragment is a short, acetylated piece of thymosin beta-4. Human studies of full-length TB4 do not establish benefits or dosing for the fragment.
Peptides
TA-1 modulates immune signaling, but that is not the same as general immune boosting. A large blinded sepsis trial found no 28-day mortality benefit.
Peptides
A regulated elamipretide product received accelerated approval for muscle strength in Barth syndrome. That narrow use does not prove general fitness or anti-aging benefits from research SS-31.
Peptides
SNAP-8 (acetyl octapeptide-3) is a topical cosmetic ingredient. Its best-known wrinkle data are a small manufacturer test, not evidence for injection or botulinum-toxin-like results.
Peptides
Sermorelin can stimulate growth-hormone release, but the hormonal response does not prove adult muscle, fat-loss, recovery, or anti-aging benefits.
Peptides
Prescription bremelanotide has evidence for acquired, generalized low sexual desire in premenopausal women. The approved autoinjector and a 10 mg research vial are not interchangeable.
Peptides
PNC-27 damaged certain cancer cells in laboratory experiments. That does not establish safety, cancer control, or a dose in people.
Peptides
PE-22-28 blocked TREK-1 channels in cell experiments and changed behavior in mice. There is no human trial establishing it as an antidepressant or defining a dose.